Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Cancer Res. 2020 Jan 16;80(7):1578–1589. doi: 10.1158/0008-5472.CAN-19-2669

Figure 3: Patient-specific evolutionary cycles delay emergence of resistance.

Figure 3:

(A,B,C,D) Model fit to PSA data from clinical trial NCT02415621 for four patients: 1001 (A), 1003 (B), 1006 (C), and 1012 (D). This trial administers continuous Lupron with adaptively administered Abiraterone, is shown (black circles). A previously published model is fit to each patient data (see (26, 36), red dashed line). Timing of treatment received under clinical protocol is indicated (top) alongside a proposed treatment of “adaptive cycles” (model-predicted PSA shown in blue). This adaptive cycling approach is able to control the tumor (shown for twenty cycles).